Use of Determination of Drug Levels to Optimize Pharmacotherapy of Heart Failure

NCT06035978 Phase 4 UNKNOWN

The aim of this study is to determine whether and how serum concentrations of the used medicinal products, including their metabolites, correlate with selected clinical indicators of heart failure (NT-proBNP concentration, 6-minute walk test, quality of life questionnaire, echocardiographic parameters, hospitalization for HFrEF, length of survival).

Details

Lead sponsor	University Hospital Ostrava
Phase	Phase 4
Status	UNKNOWN
Enrolment	100
Start date	2024-03
Completion	2026-04

Conditions

• Cardiovascular Diseases
• Heart Failure With Reduced Ejection Fraction

Interventions

• Nebivolol
• Valsartan and Sacubitril
• Carvedilol
• Bisoprolol
• Metoprolol
• Spironolactone

Primary outcomes

• Determination of the rate of significance between the serum concentration of the used medicinal products and the dose of this medicinal product — 24 month
  Determination whether the serum concentration of used medicinal products (Nebivolol, Valsartan/Sacubitril, Carvedilol, Bisoprolol, Metoprolol, Spironolactone) is more important than the dose of these medicinal products for compensating health status in patients with chronic heart failure with reduced ejection fraction (HFrEF).

Countries

Czechia